Bioorganic & Medicinal Chemistry Letters最新文献

{"title":"Structure-based discovery of sulfamoyl-ethyl-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine amides and sulfonamides as potent B-Cell Lymphoma 6 (BCL6)-BTB inhibitors","authors":"Ahmed Mamai ,&nbsp;Mohammed M. Morshed ,&nbsp;Michael Prakesch ,&nbsp;Gennady Poda ,&nbsp;Pandiaraju Subramanian ,&nbsp;Anh M. Chau ,&nbsp;Iain D.G. Watson ,&nbsp;Babu Joseph ,&nbsp;Brian Wilson ,&nbsp;Justin A. Morin ,&nbsp;Richard Marcellus ,&nbsp;Brigitte Theriault ,&nbsp;Mohammed Mohammed ,&nbsp;Ayome Abibi ,&nbsp;Manuel Chan ,&nbsp;Taira Kiyota ,&nbsp;Ahmed Aman ,&nbsp;Ratheesh Subramaniam ,&nbsp;Craig Strathdee ,&nbsp;Jeffrey Winston ,&nbsp;Rima Al-awar","doi":"10.1016/j.bmcl.2025.130471","DOIUrl":"10.1016/j.bmcl.2025.130471","url":null,"abstract":"<div><div>Diffuse Large B-Cell Lymphoma (DLBCL) is one of the most aggressive forms of lymphoid malignancies. About 40 % of patients eventually relapse and succumb to the disease within 5 years after diagnosis, underscoring the need for new treatment modalities. B-Cell Lymphoma 6 protein (BCL6) is a repressive transcription factor that is dysregulated in about 40 % of DLBCLs. As a rationale for pursuing BCL6 as a drug target, disrupting complexes between this protein and its co-repressors is thought to mitigate the downstream oncogenic effects of this pathway. However, drugging transcription factors presents a formidable undertaking since targeting protein–protein interactions has historically been challenging. In this study, we used X-ray structures of BCL6-SMRT (a silencing mediator for retinoid or thyroid-hormone receptors, also known as the nuclear receptor co-repressor 2, NCOR2) peptide and compound <strong>79-6</strong> to conduct a virtual screen of a library of 5.2 million compounds. Through this exercise, we identified the pyrrolopyridone <strong>3</strong> as a viable hit, which in turn led to the identification of pyrrolopyrimidone lead compound <strong>4</strong>. The X-ray crystal structure of <strong>4</strong> bound to the BTB (Broad-Complex, Tramtrack, and Bric à brac) domain of BCL6 revealed a large back pocket as well as a left-hand channel adjacent to the ligand that could be leveraged to optimize these compounds. Sulfonamide side chains were therefore introduced to target this space, leading to compounds <strong>11d</strong> and <strong>11e</strong> having sub-micromolar binding to the BTB domain of BCL6.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130471"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ferrocene-modified cyclic asymmetric curcumin analogs: Synthesis and enhanced antitumor activity","authors":"Haotian Xie ,&nbsp;Wenjie Xiao ,&nbsp;Ruichen Xie ,&nbsp;Lifang Xu ,&nbsp;Shuhui Ren ,&nbsp;Hanfeng Cui","doi":"10.1016/j.bmcl.2025.130446","DOIUrl":"10.1016/j.bmcl.2025.130446","url":null,"abstract":"<div><div>Tumors remain a leading cause of mortality worldwide, and existing clinical treatments face challenges such as high toxicity, poor efficacy, and multidrug resistance. Natural products have emerged as promising sources for developing anticancer drugs due to their high efficacy and low toxicity. Curcumin, a yellow polyphenolic compound with diverse biological activities (anti-tumor, antiviral, antibacterial, and anti-HIV), is particularly notable for its minimal toxic side effects. However, its clinical application is hindered by low oral bioavailability and instability. To address these limitations, this study designed and synthesized nine novel monocarbonyl curcumin analogs by removing the unstable β-diketone group and introducing ferrocene-based structures with piperidone derivatives. Using ferrocene as a starting material, these asymmetric compounds were synthesized through Vilsmeier and Claisen-Schmidt reactions, followed by structural confirmation using ¹<em>H</em> NMR, MS, and ¹³<em>C</em> NMR. Antitumor activity was evaluated against MCF-7, PC-3, and A549 tumor cells using the CCK-8 method, with curcumin as a control. Notably, several analogs exhibited dramatically enhanced potency. Compound <strong>1a</strong> was identified as the most promising derivative, showing 4.7-, 7.4-, and 2.0-fold higher potency than curcumin against A549, PC-3, and MCF-7 cells, respectively (IC₅₀ = 6.11, 5.21, and 10.37 μM vs. 28.92, 38.53, and 20.82 μM for curcumin). These findings provide a foundation for further development of ferrocene-modified curcumin analogs as potential anticancer agents.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130446"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145413910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis of novel 6-azacytidine prodrugs as potent influenza A inhibitors","authors":"Omar Moukha-Chafiq ,&nbsp;Larry D. Bratton ,&nbsp;Shuklendu D. Karyakarte ,&nbsp;Kathy Keith ,&nbsp;Yohanka Martinez-Gzegozewska ,&nbsp;Sarath C. Sarngadharan ,&nbsp;Lynn Rasmussen ,&nbsp;Bob Bostwick ,&nbsp;Ashish K. Pathak ,&nbsp;Richard Whitley ,&nbsp;Corinne E. Augelli-Szafran","doi":"10.1016/j.bmcl.2025.130473","DOIUrl":"10.1016/j.bmcl.2025.130473","url":null,"abstract":"<div><div>We report the synthesis and evaluation of novel prodrugs of 6-azacytidine (6-AzaCyd) to identify potent and bioavailable inhibitors of influenza A viruses. Prodrug <em>N</em>^<em>4</em>–2-propylpentanamide 6-AzaCyd <strong>6a</strong> was identified, through a nucleoside prodrug strategy, with a promising potency profile [H1N1-EC₉₀ = 2.6 μM, VTR = 3 at 10 μM; H3N2-EC₉₀ = 3.5 μM, VTR = 2.8 at 10 μM in MDCK cells; EC₅₀ = 2.1 μM from cap snatching polymerase U2-PB2 assay; cytotoxicity CC₅₀ &gt; 40 μM in A549 cells; CC₅₀ &gt; 20 μM in MDCK cells] and an acceptable absorption, distribution, metabolism and excretion (ADME) profile [mouse liver microsome (MLM) t_1/2 = 105 min, human liver microsome (HLM) t_1/2 = 65 min, Solubility = 77 μM]. Compound <strong>6a</strong> also exhibited acceptable pharmacokinetic properties <em>via</em> intraperitoneal (i.p<em>.</em>) route of administration. The details for the synthesis of 6-AzaCyd prodrugs and anti-influenza A activity are described herein.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130473"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145533851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis of dehydroabietic acid derivatives as mast cell stabilizers","authors":"Tao Zeng ,&nbsp;Wenchao Yu ,&nbsp;Chenming Gu ,&nbsp;Jian-Guo Fu ,&nbsp;Motahareh Asgari ,&nbsp;Yiming Li ,&nbsp;Fei Qian ,&nbsp;Chen-Guo Feng","doi":"10.1016/j.bmcl.2025.130477","DOIUrl":"10.1016/j.bmcl.2025.130477","url":null,"abstract":"<div><div>Mast cell degranulation plays a central role in IgE-driven allergic diseases, yet the therapeutic options for stabilizers remain limited. Rosinane diterpenoids, a class of natural polyphenols known for their anti-inflammatory properties, represent an attractive source for novel anti-allergic compounds. Dehydroabietic acid (DHAA), a member of this class, exhibits diverse biological activities, yet its potential in mast cell regulation remains unexplored. In this study, we designed and synthesized a series of novel DHAA derivatives. We evaluated their anti-allergic effects in IgE/antigen-stimulated bone marrow-derived mast cells (BMMCs), and found that compound <strong>4f</strong> significantly and dose-dependently inhibited IgE-mediated Ca²⁺ influx and suppressed mast cell degranulation. Moreover, <em>in vivo</em> studies demonstrated that compound <strong>4f</strong> effectively attenuated passive cutaneous anaphylaxis in mice and reduced vascular leakage. These findings indicate that compound <strong>4f</strong> represents a novel mast cell stabilizer and provides a promising structural scaffold for developing new anti-allergic therapeutics.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130477"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145533824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, synthesis, α-glucosidase inhibitory activity, and molecular docking of novel pyrazolyl–porphyrin hybrids as potential antidiabetic agents","authors":"Sagar Vijay Kumar Peddakotla ,&nbsp;Suresh Lingala ,&nbsp;Onkara Perumal ,&nbsp;M. Amaravathi ,&nbsp;G.V.P. Chandramoulia","doi":"10.1016/j.bmcl.2025.130462","DOIUrl":"10.1016/j.bmcl.2025.130462","url":null,"abstract":"<div><div>A novel series of A₂B₂ and A₄ type porphyrin derivatives bearing pyrazole moieties was efficiently synthesized and structurally characterized. These pyrazolyl–porphyrins were evaluated for their α-glucosidase inhibitory activity using <em>Saccharomyces cerevisiae</em> α-glucosidase as the target enzyme. <em>In vitro</em> enzyme assays and kinetic studies revealed that compounds <strong>6c</strong>, <strong>7b</strong>, and <strong>6d</strong> exhibited inhibitory effects comparable to the standard drug Acarbose. Notably, compound <strong>6c</strong> demonstrated the highest potency, with an IC₅₀ value of (31.36 μM<strong>)</strong>, closely matching that of Acarbose (31.69 μM) under identical experimental conditions. <em>In silico</em> molecular docking studies further supported the biological data, showing that compound <strong>6c</strong> interacts with key residues within the enzyme's active site in a binding mode similar to Acarbose. These findings suggest that pyrazolyl–porphyrin hybrids, particularly compound <strong>6c</strong>, hold promise as potential α-glucosidase inhibitors for the development of antidiabetic agents.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130462"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145463285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strengths and limitations of Ba/F3 cells in modelling FLT3-driven AML resistance","authors":"Jingmei Yang,&nbsp;Ran Friedman","doi":"10.1016/j.bmcl.2025.130456","DOIUrl":"10.1016/j.bmcl.2025.130456","url":null,"abstract":"<div><div>The Ba/F3 cell line is a widely used model in kinase drug development. Such cells are transformed to depend on a certain kinase for proliferation, and the use of an inhibitor of the kinase thus prevents their growth. We used Ba/F3 cells that expressed mutated FLT3 (FLT3-ITD), a known drug target in acute myeloid leukaemia (AML), to study drug resistance against two potent and selective inhibitors (gilteritinib and FF-10101). The cells could be made resistant to the drugs in concentrations that are similar to those in the plasma of patients, but this often required multiple secondary mutations. Several novel inhibitors, designed to be active against FLT3 mutants were tested but could not inhibit the growth of the resistant Ba/F3 cells. Several hitherto unidentified mutations in FLT3 were discovered that lead to drug resistance. These mutations were further studied using computational tools in order to understand how they lead to drug resistance. The discovery of novel mutations is significant since few patients were tested upon relapse due to lack of therapeutic options. Finally, we discuss the pros and cons of the Ba/F3 cell lines in the context of AML where patients express FLT3-ITD mutations in comparison with other cell lines, when the aim is development of drugs that overcome resistance.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130456"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis and antitumor activities of quaternary carbon-containing selenolactones","authors":"Danqing Li ,&nbsp;Yumiao Zhen ,&nbsp;Ran Tang ,&nbsp;Boying Wang ,&nbsp;Haijing Zhong ,&nbsp;Xiaojian Jiang ,&nbsp;Ying-Yeung Yeung","doi":"10.1016/j.bmcl.2025.130439","DOIUrl":"10.1016/j.bmcl.2025.130439","url":null,"abstract":"<div><div>The cytotoxicity of α-<em>exo</em>-methylene-lactones has been extensively studied. However, further study of the α-<em>exo</em>-methylene-lactones for anticancer application was hampered primarily by its poor selectivity and solubility. In the present work, a series of α-<em>exo</em>-methylene-selenolactone derivatives bearing amine substituent, selenium functionality and quaternary carbon center were synthesized and evaluated for their anticancer activities. The most potent compound, <strong>2d</strong>, was about 9-fold more selective for cancer cells than normal cells. Moreover, <strong>2d</strong> significantly inhibited tumor growth in mouse xenograft model and had no observable toxic effect.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130439"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145342480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"α2C Adrenoceptor antagonist KMCA-0011 alleviated depressive-like behaviors in a maternal separation mouse model","authors":"Kobeom Seo ,&nbsp;Mijin Jeon ,&nbsp;Ju Eun Han ,&nbsp;Jinwon Hong ,&nbsp;Do Hyeon Kim ,&nbsp;Jung Hwan Choi ,&nbsp;Seo Yun Jung ,&nbsp;Kyeong-Man Kim ,&nbsp;Dong Hyun Kim ,&nbsp;Jong Hoon Ryu ,&nbsp;Jae Yeol Lee","doi":"10.1016/j.bmcl.2025.130467","DOIUrl":"10.1016/j.bmcl.2025.130467","url":null,"abstract":"<div><div>Despite the widespread use of monoaminergic antidepressants, their clinical efficacy is often limited by delayed onset and adverse effects. Targeting the α_2C adrenoceptor (AR) has emerged as a promising strategy to overcome these limitations. Here, a series of benzoxazole and oxalamide derivatives were designed, synthesized, and biologically evaluated as potential antidepressants targeting α_2C AR. Among them, <strong>11e</strong> (KMCA-0011), <strong>21b</strong> (KMCA-0002), and <strong>21e</strong> (KMCA-0028) exhibited the highest binding affinity. Molecular docking studies provided a rationale for the differences in their binding affinities. These compounds demonstrated antagonistic activity by inhibiting ERK phosphorylation without agonistic effects. In a maternal separation (MS) mouse model, all three compounds significantly alleviated depressive-like behaviors, with <strong>11e</strong> (KMCA-0011) and <strong>21e</strong> (KMCA-0028) showing the most consistent efficacy. Mechanistically, <strong>11e</strong> (KMCA-0011) increased hippocampal brain-derived neurotrophic factor (BDNF) levels and restored corticosterone-induced impairments in long-term potentiation (LTP), indicating modulation of synaptic plasticity. Additionally, <strong>11e</strong> (KMCA-0011) and <strong>21e</strong> (KMCA-0028) displayed favorable ADME profiles, including high plasma stability and minimal CYP inhibition. Given the predicted limited blood–brain barrier (BBB) permeability of <strong>21e</strong> (KMCA-0028), these results collectively identify <strong>11e</strong> (KMCA-0011) as a promising lead compound that demonstrates robust antidepressant-like activity, likely mediated through α_2C AR antagonism and BDNF-dependent neuroplastic mechanisms.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130467"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145476509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of O-alkylated derivative of piperine as Nav1.7 channel inhibitor for the treatment of pain","authors":"Vikrant Nawal Vikram ,&nbsp;Madhavi Ranawat ,&nbsp;Aditya Singh ,&nbsp;Shiv Kumar ,&nbsp;Ashutosh Sharma ,&nbsp;Shivani Yadav ,&nbsp;Vikash Kumar ,&nbsp;Aravind Singh Kshatri ,&nbsp;Tadigoppula Narender","doi":"10.1016/j.bmcl.2025.130461","DOIUrl":"10.1016/j.bmcl.2025.130461","url":null,"abstract":"<div><div>Millions of people are being affected by chronic pain, and it is insufficiently addressed by the current classes of analgesics. Nav1.7 channels have emerged as promising targets in this pain context since their systemic inhibition can cancel pain perception altogether. In this work, we report a novel, O-alkylated piperine derivative <strong>3ag</strong> as an inhibitor of Nav1.7 channels with an IC₅₀ of 3.10 μM. Furthermore, this molecule displayed an oral analgesic efficacy in a CFA inflammatory pain model at 10 mg/kg. Based on our findings, this molecule could be used as a starting point for the development of new Nav1.7-specific blockers for anti-nociception.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130461"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145457067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydantion indolinones as AANAT inhibitors","authors":"Nicole Wandrey ,&nbsp;Jake Boley ,&nbsp;Dirce Gómez-Galicia ,&nbsp;Mackinzi Hill ,&nbsp;Mason Bach ,&nbsp;Sidney Gawrych ,&nbsp;Mackenzie Hagemeister ,&nbsp;Philip A. Cole ,&nbsp;Michael A. Moxley ,&nbsp;Allen A. Thomas","doi":"10.1016/j.bmcl.2025.130459","DOIUrl":"10.1016/j.bmcl.2025.130459","url":null,"abstract":"<div><div>Arylalkylamine <em>N</em>-acetyltransferase (AANAT) is a key enzyme in melatonin biosynthesis and a regulator of circadian rhythm, with potential relevance to mood disorders such as seasonal affective disorder (SAD). We report a series of hydantoin indolinone-based AANAT inhibitors, developed as more stable alternatives to a previously reported rhodanine scaffold. Guided by docking studies and prior structure-activity data, we modified four regions of the molecule to improve potency. Substitution at the 5-position of the indolinone ring led to marked increases in activity, with compound <strong>5g</strong> (bearing a CH₃CO₂CH₂- substituent) resulting in an IC₅₀ of 1.1 μM—representing a 19-fold improvement over the parent compound. Kinetic mechanism studies were also conducted with respect to acetyl-CoA and serotonin to explore inhibitor binding. These findings establish a promising starting point for the development of more potent AANAT inhibitors as chemical probes for studying melatonin's function.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130459"},"PeriodicalIF":2.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145426338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}